NCT06792253
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
Clinical trial condition
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Explore clinical trials studying Relapsed/Refractory Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.
8 public trials
3 recruiting studies
Relapsed/Refractory Diffuse Large B-cell Lymphoma trial results
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
- Baoding NO.1 Central Hospital Baoding, China
- Beijing GoBroad Hospital Beijing, China
- BEIJING TONGREN HOSPITAL, Capital Medical University Beijing, China
NCT06902012
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Zhujiang Hospital Guangzhou, Guangdong, China
Not yet recruiting
Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
NCT07748364
- Conditions
- Dendritic Cell Sarcoma, Interdigitating, Disease Attributes, Hemic and Lymphatic Diseases, +18 more
- Locations
-
- Icahn School of Medicine at Mount Sinai New York, United States
Active, not recruiting
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
- Locations
-
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers Chandler, Arizona, United States
- Arizona Oncology Associates Tucson, Arizona, United States
- The Oncology Institute (TOI) Clinical Research Cerritos, California, United States
- Norton Cancer Institute, St. Matthews Louisville, Kentucky, United States
Active, not recruiting
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT06601504
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Fujian Medical University Union Hospital Fuzhou, Fujian, China
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
- Guangxi Medical University Cancer Hospital Nanning, Guangxi, China
- Wuhan Union Hospital of China Wuhan, Hebei, China
NCT04436107
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
- Sun Yat Sen University Cancer Center Guangzhou, Guangdong, China
- Henan Cancer Hospital Zhengzhou, Henan, China
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China
NCT03886831
- Conditions
- Adenocarcinoma, Adenoid Cystic Carcinoma, Anemia, +39 more
- Locations
-
- Banner MD Anderson Cancer Center Gilbert, Arizona, United States
- UCSF Precision Cancer Medicine Building San Francisco, California, United States
- Christiana Care Health Services, Christiana Hospital Newark, Delaware, United States
- Florida Cancer Specialists Lake Mary, Florida, United States